AstraZeneca Collaborates with Syneron Bio to Develop Macrocyclic Peptides for Chronic Diseases
Shots:
- Syneron Bio & AstraZeneca have entered into a strategic collaboration to develop novel macrocyclic peptides for the treatment of chronic diseases, leveraging Syneron Bio’s Synova platform
- As per the deal, Syneron Bio will receive $75M upfront & in near-term milestones, ~$3.4B in development & commercial milestones, plus net sales-based tiered royalties, along with an equity investment. Syneron to expand its Beijing R&D center under this partnership
- Synova platform is an advanced, high-throughput platform for macrocyclic peptide drug R&D, designed to support research of potential treatments for chronic diseases, incl. rare, autoimmune, & metabolic disorders
Ref: Prnewswire | Image: AstraZeneca
Related News:- AstraZeneca Reports P-III (CALYPSO) Trial Data of Eneboparatide for Chronic Hypoparathyroidism (HypoPT)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
